Panagora Asset Management Inc Cassava Sciences Inc Transaction History

Panagora Asset Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 10, 2021	SELL	$41.79 - $135.3 $148,855 - $481,938	-3,562 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$32.15 - $89.72 $38,997 - $108,830	-1,213 Reduced 25.4%	3,562 $304,000
Q1 2021 May 12, 2021	BUY	$7.09 - $87.95 $16,434 - $203,868	2,318 Added 94.34%	4,775 $214,000
Q4 2020 Feb 10, 2021	BUY	$6.79 - $12.25 $4,753 - $8,575	700 Added 39.84%	2,457 $17,000
Q3 2020 Nov 13, 2020	BUY	$2.86 - $11.51 $5,025 - $20,223	1,757 New	1,757 $20,000
Q3 2019 Nov 12, 2019	SELL	$1.04 - $1.45 $39,204 - $54,660	-37,697 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$1.02 - $1.34 $1,412 - $1,855	-1,385 Reduced 3.54%	37,697 $46,000
Q1 2019 May 15, 2019	BUY	$0.92 - $1.29 $35,955 - $50,415	39,082 New	39,082 $50,000

196

13.8M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $101M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.